These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18948998)

  • 1. A decade of the Fast Track programme.
    Reichert JM; Rochon SL; Zhang BD
    Nat Rev Drug Discov; 2008 Nov; 7(11):885-6. PubMed ID: 18948998
    [No Abstract]   [Full Text] [Related]  

  • 2. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 3. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 5. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 6. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in FDA drug classification and priority review policy.
    Crawford SY
    Am J Hosp Pharm; 1992 Oct; 49(10):2383, 2386. PubMed ID: 1442812
    [No Abstract]   [Full Text] [Related]  

  • 9. Food and drug administration expanded access to treatment: implications for oncology patients.
    Freedman RS; Markman M
    Cancer; 2007 Jun; 109(11):2157-60. PubMed ID: 17450587
    [No Abstract]   [Full Text] [Related]  

  • 10. Controlling type I error rate for fast track drug development programmes.
    Shih WJ; Ouyang P; Quan H; Lin Y; Michiels B; Bijnens L
    Stat Med; 2003 Mar; 22(5):665-75. PubMed ID: 12587098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2008; 21(1):36-43. PubMed ID: 18301808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 13. [Off-label use in oncology. The Italian choice].
    Felicetti V; Gremigni U; Cifaldi L
    Recenti Prog Med; 2008 Dec; 99(12):612-5. PubMed ID: 19388222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 15. An audience with... Janet Woodcock discusses the role of the FDA in improving pharma productivity.
    Woodcock J
    Nat Rev Drug Discov; 2004 Nov; 3(11):904. PubMed ID: 15558859
    [No Abstract]   [Full Text] [Related]  

  • 16. "Fast tracking" drug approvals: is consumer safety being compromised?
    Jacobsen K
    QRC Advis; 2000 Jun; 16(8):5-9. PubMed ID: 10977137
    [No Abstract]   [Full Text] [Related]  

  • 17. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

  • 18. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW; Rappaport BA
    Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
    [No Abstract]   [Full Text] [Related]  

  • 19. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
    Moss RW
    New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer and the constitution--choice at life's end.
    Annas GJ
    N Engl J Med; 2007 Jul; 357(4):408-13. PubMed ID: 17652658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.